Zynerba Pharmaceuticals Stock Profit Margin
Zynerba Pharmaceuticals fundamentals help investors to digest information that contributes to Zynerba Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Zynerba Stock. The fundamental analysis module provides a way to measure Zynerba Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zynerba Pharmaceuticals stock.
Zynerba |
Zynerba Pharmaceuticals Company Profit Margin Analysis
Zynerba Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Zynerba Pharmaceuticals has a Profit Margin of 0.0%. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Zynerba Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zynerba Pharmaceuticals' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zynerba Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zynerba Pharmaceuticals by comparing valuation metrics of similar companies.Zynerba Pharmaceuticals is currently under evaluation in profit margin category among its peers.
Zynerba Fundamentals
| Return On Equity | -0.87 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 28.33 M | |||
| Shares Outstanding | 53.94 M | |||
| Shares Owned By Insiders | 6.07 % | |||
| Shares Owned By Institutions | 12.12 % | |||
| Number Of Shares Shorted | 419.98 K | |||
| Price To Earning | (3.84) X | |||
| Price To Book | 0.54 X | |||
| Price To Sales | 1,153 X | |||
| EBITDA | (34.62 M) | |||
| Net Income | (35.04 M) | |||
| Cash And Equivalents | 62.49 M | |||
| Cash Per Share | 1.44 X | |||
| Total Debt | 334.43 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 6.89 X | |||
| Book Value Per Share | 0.57 X | |||
| Cash Flow From Operations | (23.03 M) | |||
| Short Ratio | 0.26 X | |||
| Earnings Per Share | (0.80) X | |||
| Target Price | 1.25 | |||
| Number Of Employees | 25 | |||
| Beta | 1.19 | |||
| Market Capitalization | 70.12 M | |||
| Total Asset | 55.52 M | |||
| Retained Earnings | (274.52 M) | |||
| Working Capital | 45.6 M | |||
| Current Asset | 43.42 M | |||
| Current Liabilities | 3.94 M | |||
| Net Asset | 55.52 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Zynerba Stock
If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |